With regard to mTOR inhibitors, everolimus and sirolimus are two agents with Food and Drug Administration approval to treat various systemic manifestations of TSC, including subependymal giant cell astrocytomas, angiomyolipomas and lymphangioleiomyomatosis [119]. Here, MTOR is linked to astrocytoma (excluding glioblastoma).